Advertisement

Advertisement

38th Annual Miami Breast Cancer Conference

Breast Cancer

Breast Cancer in 2030: Predictions From a Breast Cancer Luminary

According to George W. Sledge, Jr, MD, FASCO, Professor of Medicine in the Division of Oncology at Stanford University Medical Center, by the beginning of the next decade, clinicians will be aided by ...

Breast Cancer

Personalizing Treatment of Early HER2-Positive Breast Cancer

With several pivotal trials providing evidence for the escalation and de-escalation of anti-HER2 therapy in certain early breast cancer scenarios, personalized treatment is possible. How can clinician...

Breast Cancer

Beyond CDK4/6 Inhibitors in Metastatic Breast Cancer: What’s Next?

Because of their well-established efficacy, inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) are the standard of care in the treatment of hormone receptor–positive, HER2-negative metastatic bre...

Breast Cancer

Improving Screening of Dense Breasts With Newer MRI Technologies

Women with dense breasts are increasingly being screened with magnetic resonance imaging (MRI), which is clearly the best way to detect small cancers in this population, according to Elizabeth Morris,...

Breast Cancer

Early Triple-Negative Breast Cancer: Are Checkpoint Inhibitors Ready for Neoadjuvant or Adjuvant Use?

Recent clinical trials have been encouraging for the neoadjuvant or adjuvant use of immune checkpoint inhibitors in triple-negative breast cancer, but is this approach ready for the clinic? This quest...

Breast Cancer
Immunotherapy

Role of Antibody-Drug Conjugates Across Breast Cancer Subtypes

For the treatment of breast cancer, antibody-drug conjugates are emerging as effective players that could impact all subtypes of this disease, according to Kevin Kalinsky, MD, MS, Director of the Glen...

Breast Cancer
Issues in Oncology

Younger vs Older Women With Breast Cancer: Understanding the Differences

Younger women with breast cancer differ from their older counterparts in ways that should be appreciated by their clinicians, according to Ann H. Partridge, MD, MPH, FASCO, Vice Chair of Medical Oncol...

Breast Cancer
Immunotherapy

Novel HER2-Targeted Therapies Pose Sequencing Challenges

With three new HER2-targeted therapies approved in the past 15 months alone, the treatment landscape for patients with metastatic breast cancer has become increasingly crowded. In the third-line setti...

Breast Cancer

Miami Breast Cancer Conference: Genomic Assays Show Utility in Predicting Pathologic Complete Response Rate in Pre- and Postmenopausal Patients With Breast Cancer

New data from the prospective Neoadjuvant Breast Symphony Trial (NBRST), which demonstrated the predictive and prognostic abilities of the MammaPrint and BluePrint assays and underpinned their preoper...

Breast Cancer
Immunotherapy

Miami Breast Cancer Conference: Updated DESTINY-Breast01 Results Show Trastuzumab Deruxtecan-nxki Delivers Durable Responses

In updated results from the pivotal DESTINY-Breast01 trial, trastuzumab deruxtecan-nxki (T-DXd) demonstrated high rates of durable responses consistent with prior results, with encouraging progression...

Breast Cancer

Miami Breast Cancer Conference: Study Examines Response to Neoadjuvant Chemotherapy in Hispanic and Black Patients

Few studies documenting the benefit of neoadjuvant chemotherapy for breast cancer have been conducted in minority populations. A single-institution study reported at PER's Miami Breast Cancer Conferen...

Advertisement

Advertisement



Advertisement